Updated efficacy and safety results from a global phase 2, open-label, single-arm study (NP28673) of alectinib in crizotinib-refractory ALK plus non-small-cell lung cancer (NSCLC) Meeting Abstract

Industry Collaboration International Collaboration

cited authors

  • Barlesi, F., Dingemans, A. M. C., Ou, I., Ahn, J. S., Petris, L. D., Kim, D. W., Yang, J. C. H., Hughes, B., Lena, H., Moro-Sibilot, D., Bearz, A., Viteri, S., Mekhail, T., Spira, A., Zeaiter, A., Bordogna, W., Sturm, C., Golding, S., Morcos, P. N., Govindan, R.

authors

Publication Date

  • September 1, 2015

webpage

published in

category

start page

  • S635

end page

  • S635

volume

  • 51

WoS Citations

  • 2
  • 3

WoS References

  • 0